CoChat

Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9

E, Jifu, Xing, Junjie, Gong, Haifeng, He, Jian, Zhang, Wei · 2015 · Tumor Biology

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

Although epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) cetuximab are used widely to treat KRAS wild-type metastatic colorectal cancer (mCRC), patients become resistant by various mechanisms, including KRAS, BRAF, and PIK3CA mutations, thereafter relapsing. AZD6244 is a potent, selective, and orally available MEK1/2 inhibitor. In this study, we investigated the mechanisms of AZD6244 alone or with BEZ235, an orally available potent inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), in a KRAS and PIK3CA mutation CRC xenograft model. HCT116 (KRAS (G13D) , PIK3CA (H1047R) mutant) cells were subcutaneously injected into the nude mice. Mice were randomly assigned to treatment with vehicle, cetuximab, AZD6244, BEZ235, or AZD6244 plus BEZ235, for up to 3 weeks; then, all mice were sacrificed, and tumor tissues were subjected to Western blot analysis and immunohistochemical staining. AZD6244 or BEZ235 slightly inhibit tumor growth of HCT116 xenografts, and the combination treatment markedly enhanced their antitumor effects. However, cetuximab had no effect on tumor growth. Western blot analysis and immunohistochemical staining revealed that treatment with AZD6244 or BEZ235 could significantly reduce the phosphorylation level of ERK1/2 or AKT in HCT116 tumor tissues. More interesting, the antiangiogenic effects were substantially enhanced when the agents were combined which may due to the reduced expression of VEGF and matrix metallopeptidase-9 (MMP-9) in tumor tissues. These results suggest that the combination of a selective MEK inhibitor and a PI3K/mTOR inhibitor was effective in CRC harboring with KRAS and PIK3CA mutations. The mechanisms of synergistic antitumor effects may be due to antiangiogenesis.

Overview

Integrity signals

Registry

Crossref · 10.1007/s13277-014-2667-5

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 28 references

Cited by

See all 29

Metadata

Authors
E, J., Xing, J., Gong, H., He, J., & Zhang, W.
Affiliations
Second Military Medical University (CN)
Corresponding author
Zhang, Wei
Venue
Tumor Biology
Published
2014-10-19
Volume
36
Issue
2
Pages
1091-1097
ISSN
  • 1010-4283 (ISSN-L)
  • 1423-0380
OpenAlex
W2047946511
Cited by
29
References
28
Citations by year
2026: 1 · 2025: 2 · 2024: 2 · 2023: 1 · 2021: 2 · 2020: 1 · 2019: 1 · 2018: 6 · 2017: 5 · 2016: 3 · 2015: 5
FWCI
2.09
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Tumor Biology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Keywords
MEK inhibition, PI3K/mTOR inhibition, KRAS mutation, PIK3CA mutation, colorectal cancer, selumetinib, BEZ235, cetuximab, combination therapy, angiogenesis inhibition, vascular endothelial growth factor, MMP-9, ERK1/2 phosphorylation, Akt phosphorylation, HCT116 xenograft, cetuximab resistance
MeSH terms
Cetuximab, Animals, Benzimidazoles, Humans, Imidazoles, Proto-Oncogene Proteins, Quinolines, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), ras Proteins, Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, Matrix Metalloproteinase 9, Xenograft Model Antitumor Assays, Vascular Endothelial Growth Factor A, HCT116 Cells, Protein Kinase Inhibitors, MAP Kinase Kinase 1, Mice, Class I Phosphatidylinositol 3-Kinases, TOR Serine-Threonine Kinases, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9. https://app.cochat.ai/papers/10.1007/s13277-014-2667-5
The paper
E, J., Xing, J., Gong, H., He, J., & Zhang, W. (2015). Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9. Tumor Biology. https://doi.org/10.1007/s13277-014-2667-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.